Apricity Health
Tuesday, February 27, 2024
Uris
Oncology
Apricity Health is a precision oncology company at the intersection of digital health, AI and biotechnology. It pioneers Dynamic Precision™, which mines longitudinal clinical and molecular data from patients before and during treatment to pinpoint druggable adaptive resistance mechanisms with associated blood-based biomarkers, thus dramatically increasing the probability of success in downstream drug development. Apricity has identified over 10 validated targets with biomarkers, with lead program advancing to IND in 2024. Since every drug has non-responders, Apricity develops and operates a technology-enabled virtual care platform to augment real world care for patient benefits, while in parallel gaining access to real world data and diverse patient populations to generate, purposefully and prospectively, the right kind of longitudinal patient data for Dynamic Precision™ drug discovery.
Speakers
State
Texas
Country
United States
Website
https://apricity-health.com/
CEO/Top Company Official
Lynda Chin
Lead Product in Development
Lead drug discovery program is a human monoclonal antibody targeting a myeloid immune checkpoint.
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
A pipeline of 11 target-biomarker pairs.
Lead program in CMC, licensed to a wholly-owned subsidiary, which is looking to partner or raise independent dilutive capital.
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}